Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects

Robert S. Rosenson, R. Scott Wright, Michael Farkouh, Jorge Plutzky

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Clinical trials of cardiovascular disease (CVD) prevention in patients with type 2 diabetes mellitus primarily have been directed at the modification of a single major risk factor; however, in trials that enroll patients with and without diabetes, the absolute risk in CVD events remains higher in patients with diabetes. Efforts to reduce the macrovascular and microvascular residual risk have been directed toward a multifactorial CVD risk-factor modification; nonetheless, long-term complications remain high. Dual-peroxisome proliferator-activated receptor (PPAR) α/γ agonists may offer opportunities to lower macrovascular and microvascular complications of type 2 diabetes mellitus beyond the reductions achieved with conventional risk-factor modification. The information presented elucidates the differentiation of compound-specific vs class-effect properties of PPARs as the basis for future development of a new candidate molecule. Prior experience with thiazolidinediones, an approved class of PPARγ agonists, and glitazars, investigational class of dual-PPARα/γ agonists, also provides important lessons about the risks and benefits of targeting a nuclear receptor while revealing some of the future challenges for regulatory approval.

Original languageEnglish (US)
Pages (from-to)672-680
Number of pages9
JournalAmerican Heart Journal
Volume164
Issue number5
DOIs
StatePublished - Nov 1 2012

Fingerprint

Peroxisome Proliferator-Activated Receptors
Cardiovascular Diseases
Type 2 Diabetes Mellitus
Thiazolidinediones
Diabetes Complications
Therapeutics
Cytoplasmic and Nuclear Receptors
Clinical Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. / Rosenson, Robert S.; Wright, R. Scott; Farkouh, Michael; Plutzky, Jorge.

In: American Heart Journal, Vol. 164, No. 5, 01.11.2012, p. 672-680.

Research output: Contribution to journalArticle

@article{ffc4d8ae3b3848bdb5743bf33d51ed5e,
title = "Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects",
abstract = "Clinical trials of cardiovascular disease (CVD) prevention in patients with type 2 diabetes mellitus primarily have been directed at the modification of a single major risk factor; however, in trials that enroll patients with and without diabetes, the absolute risk in CVD events remains higher in patients with diabetes. Efforts to reduce the macrovascular and microvascular residual risk have been directed toward a multifactorial CVD risk-factor modification; nonetheless, long-term complications remain high. Dual-peroxisome proliferator-activated receptor (PPAR) α/γ agonists may offer opportunities to lower macrovascular and microvascular complications of type 2 diabetes mellitus beyond the reductions achieved with conventional risk-factor modification. The information presented elucidates the differentiation of compound-specific vs class-effect properties of PPARs as the basis for future development of a new candidate molecule. Prior experience with thiazolidinediones, an approved class of PPARγ agonists, and glitazars, investigational class of dual-PPARα/γ agonists, also provides important lessons about the risks and benefits of targeting a nuclear receptor while revealing some of the future challenges for regulatory approval.",
author = "Rosenson, {Robert S.} and Wright, {R. Scott} and Michael Farkouh and Jorge Plutzky",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.ahj.2012.06.023",
language = "English (US)",
volume = "164",
pages = "672--680",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects

AU - Rosenson, Robert S.

AU - Wright, R. Scott

AU - Farkouh, Michael

AU - Plutzky, Jorge

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Clinical trials of cardiovascular disease (CVD) prevention in patients with type 2 diabetes mellitus primarily have been directed at the modification of a single major risk factor; however, in trials that enroll patients with and without diabetes, the absolute risk in CVD events remains higher in patients with diabetes. Efforts to reduce the macrovascular and microvascular residual risk have been directed toward a multifactorial CVD risk-factor modification; nonetheless, long-term complications remain high. Dual-peroxisome proliferator-activated receptor (PPAR) α/γ agonists may offer opportunities to lower macrovascular and microvascular complications of type 2 diabetes mellitus beyond the reductions achieved with conventional risk-factor modification. The information presented elucidates the differentiation of compound-specific vs class-effect properties of PPARs as the basis for future development of a new candidate molecule. Prior experience with thiazolidinediones, an approved class of PPARγ agonists, and glitazars, investigational class of dual-PPARα/γ agonists, also provides important lessons about the risks and benefits of targeting a nuclear receptor while revealing some of the future challenges for regulatory approval.

AB - Clinical trials of cardiovascular disease (CVD) prevention in patients with type 2 diabetes mellitus primarily have been directed at the modification of a single major risk factor; however, in trials that enroll patients with and without diabetes, the absolute risk in CVD events remains higher in patients with diabetes. Efforts to reduce the macrovascular and microvascular residual risk have been directed toward a multifactorial CVD risk-factor modification; nonetheless, long-term complications remain high. Dual-peroxisome proliferator-activated receptor (PPAR) α/γ agonists may offer opportunities to lower macrovascular and microvascular complications of type 2 diabetes mellitus beyond the reductions achieved with conventional risk-factor modification. The information presented elucidates the differentiation of compound-specific vs class-effect properties of PPARs as the basis for future development of a new candidate molecule. Prior experience with thiazolidinediones, an approved class of PPARγ agonists, and glitazars, investigational class of dual-PPARα/γ agonists, also provides important lessons about the risks and benefits of targeting a nuclear receptor while revealing some of the future challenges for regulatory approval.

UR - http://www.scopus.com/inward/record.url?scp=84868607245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868607245&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2012.06.023

DO - 10.1016/j.ahj.2012.06.023

M3 - Article

C2 - 23137497

AN - SCOPUS:84868607245

VL - 164

SP - 672

EP - 680

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -